Determination of Lorazepam in Plasma of Patients during Status Epilepticus by High-Performance Liquid Chromatography

Abstract
A reversed-phase high-performance liquid chromatography method for the determination of lorazepam in human plasma has been developed. The method was used to analyze plasma samples obtained from patients who were treated with 0.1 mg/kg of intravenous lorazepam during status epilepticus. The detection limit for lorazepam was 5 ng/ml. None of the most commonly used antiepileptic drugs interfere with this lorazepam analysis.

This publication has 3 references indexed in Scilit: